Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer

[Display omitted] New targeted therapy approaches for certain subtypes of breast cancer, such as triple-negative breast cancers and other aggressive phenotypes, are desired. High levels of the mitotic checkpoint kinase Mps1/TTK have correlated with high histologic grade in breast cancer, suggesting...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bioorganic & medicinal chemistry 2017-04, Vol.25 (7), p.2156-2166
Hauptverfasser:	Sugimoto, Yasuro, Sawant, Dwitiya B., Fisk, Harold A., Mao, Liguang, Li, Chenglong, Chettiar, Somsundaram, Li, Pui-Kai, Darby, Michael V., Brueggemeier, Robert W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Breast cancer Breast Neoplasms - drug therapy Cell Cycle Proteins - antagonists & inhibitors Centrosome amplification Female Humans Mice Mice, Nude Mps-1 Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Protein-Serine-Threonine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - pharmacology Pyrimidines - therapeutic use Pyrrolopyrimidine analogues Spindle checkpoint kinases TTK
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!